EXTRACELLULAR MATRIX CONDITION IN CASE OF HCVASSOCIATED LIVER FIBROSIS
https://doi.org/10.15789/1563-0625-2017-1-35-44
Abstract
Imbalance of the proteolysis/antiproteolysis system is known to be among key components of immunofibrogenesis of liver in cases of chronic hepatitis C. To evaluate these aspects, we studied several factors of liver tissue remodeling in blood serum and local samples from HCV patients associated with liver fibrosis. We determined the levels of matrix metalloproteinase-9 (MMP-9), tissue inhibitor of matrix metalloproteinase-1 (TIMP-1), MMP-9/TIMP-1 and MMP-9/TIMP-2 complexes. Clinical, laboratory and instrumental examinations have been made for 81 patients with chronic hepatitis C who did not receive antiviral therapy, and 22 healthy volunteers. Extracellular matrix protein (ECM) profile was studied in 103 serum blood samples and 32 liver supernates using ELISA technique. Statistically significant increase of MMP-9 contents (p < 0.05) and its complexes with TIMP-1 (p < 0.05) and TIMP-2 (p < 0.01), as well as low levels of type 1 inhibitor (p < 0.05) were revealed in blood serum of HCV-infected patients, as compared with control group. Protein assays in liver supernates of hepatitis C patients reflecting extracellular matrix state revealed an eight-fold increase in MMP-9/ TIMP-1 complex, as compared with control group (p < 0.05). The values of other proteolytic/antiproteolytic factors proved to be low (p < 0.05). An imbalance in protease contents in blood serum and liver biopsies was revealed, showing differently directed changes. I.e., serum values of MMP-9, TIMP-1 and MMP-9/TIMP-2 during transition of liver fibrosis to cirrhosis (F0 to F4) became decreased (p < 0.05), associated with increased liver concentrations of these proteolytic enzymes (p < 0.05). In summary, we conclude that the data obtained in our study suggest an imbalance of proteolysis/antiproteolysis system leads to a dysregulated liver tissue remodeling in patients with chronic hepatitis C.
About the Authors
I. S. Gorelova
Pacific State Medical University
Russian Federation
Russian Federation
PhD (Medicine), Assistant Professor, Department of Infectious Diseases,
690089, Vladivostok, Tukhachevsky str., 56-50
L. F. Sklyar
Pacific State Medical University
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Department of Infectious Diseases,
Vladivostok
E. V. Markelova
Pacific State Medical University
Russian Federation
Russian Federation
PhD, MD (Medicine), Professor, Head, Department of Normal and Pathological Physiology,
Vladivostok
A. I. Simakova
Pacific State Medical University
Russian Federation
Russian Federation
PhD, MD (Medicine), Associate Professor, Head, Department of Infectious Diseases,
Vladivostok
I. V. Zenin
Pacific State Medical University
Russian Federation
Russian Federation
Graduate Student, Department of Infectious Diseases, Pacific State Medical University,
Vladivostok
References
1. Бабак О.Я., Колесникова Е.В., Кравченко Н.А. Фиброз печени: современные представления о механизмах, способах диагностики и лечения // Сучасна гастроентерологiя, 2009. № 2 (46) С. 5-17. [Babak O.Ya., Kolesnikova E.V., Kravchenko N.A. Liver fibrosis: current concepts of mechanisms, diagnostic and therapeutic approaches. Suchasna gastroenterologiya = Modern Gastroenterology, 2009, no. 2 (46), pp. 5-17. (In Ukr.)]
2. Вельков В.В. Сывороточные биомаркеры фиброза печени: до свидания, биопсия? М.: Lomonosoff Print, 2009. 40 с. [Vel’kov V.V. Serum biomarkers of liver fibrosis: farewell to the biopsy?] Moscow: Lomonosoff Print, 2009. 40 p.
3. Иванис В.А., Маркелова Е.В., Скляр Л.Ф. Значение иммунных механизмов в патогенезе некоторых острых и хронических вирусных инфекций // Инфекция и иммунитет, 2011. Т. 1, № 4. С. 373-377. [Ivanis V.A., Markelova E.V., Sklyar L.F. Significance of immune mechanisms in pathogenesis of some acute and chronic viral infectious diseases. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2011, Vol. 1, no. 4, pp. 373-377. (In Russ.)] http://dx.doi.org/10.15789/2220-7619-2011-4-373-377
4. Нагоев Б.С., Понежева Ж.Б. Роль цитокиновой системы в патогенезе хронического гепатита С // Инфекционные болезни, 2009. Т. 7, № 4. С. 12-17. [Nagoev B.S., Ponezheva Zh.B. The role of cytokine system in pathogenesis of chronic hepatitis. Infektsionnye bolezni = Infectious Diseases , 2009, Vol. 7, no. 4, pp. 12-17. (In Russ.)]
5. Назаров П.Г. Реактанты острой фазы воспаления. СПб.: Наука, 2001. 423 с. [Nazarov P.G. Acute phase reactants in inflammation]. St. Petersburg: Science, 2001. 423 p.
6. Останин А.А., Гельфгат Е.Л., Шипунов М.В., Шевела Е.Я., Курганова Е.В., Хван Л.А., Пальцев А.И., Старостина Н.М., Черных Е.Р. Прогностическая модель неинвазивной диагностики фиброза печени у больных хроническими вирусными гепатитами // Медицинская иммунология, 2008. Т. 10, № 4-5. С. 405-414.
7. [Ostanin A.A., Gelfgadt E.L., Shipunov M.V., Shevela E.Ya., Kurganova E.V., Khvan L.A., Paltsev A.I., Starostina N.M., Chernykh E.R. A predictive model for non-invasive evalution of liver fibrosis in patients with chronic hepatitis virus infection. Meditsinskaya immunologiya = Medical Immunology (Russia), 2008, Vol. 10, no. 4-5, pp. 405-414. (In Russ.)] http://dx.doi.org/10.15789/1563-0625-2008-4-5-405-414
8. Сысоев К.А., Чухловин А.Б., Шахманов Д.М., Жданов К.В., Тотолян А.А. Профиль цитокинов и хемокинов в плазме крови пациентов с хроническим гепатитом С // Инфекция и иммунитет, 2013. Т. 3, № 1. С. 49-58. [Sysoev K.A., Chukhlovin A.V., Shakhmanov D.M., Zhdanov K.V., Totolian A.A. Cytokines and chemokines in the blood plasma of patients with chronic hepatitis C. Infektsiya i immunitet = Russian Journal of Infection and Immunity, 2013, Vol. 3, no. 1, pp. 49-58. (In Russ.)] http://dx.doi.org/10.15789/2220-7619-2013-1-49-58
9. Сторожаков Г.И., Ивкова А.Н. Патогенетические аспекты фиброгенеза при хронических заболеваниях печени // Клинические перспективы гастроэнтерологии, гепатологии, 2009. № 2. С. 3-10. [Storozhakov G.I., Ivkova A.N. Pathogenetic aspects of fibrogenesis in chronic liver diseases. Klinicheskie perspektivy gastroenterologii, gepatologii = Clinical Gerspectives of Gastroenterology, Hepatology, 2009, no. 2, pp. 3-10. (In Russ.)]
10. Arthur M.J. Fibrogenesis II. Metalloproteinases and their inhibitors in liver fibrosis. Am. J. Physiol. Gastrointest. Liver Physiol, 2000. Vol. 279, no. 2, pp. 245-249.
11. Baranova A., Lal P., Birerdinc A., Younossi Z.M. Non-Invasive markers for hepatic fibrosis. BMC Gastroenterol., 2011, Vol. 11, no. 91, pp. 1-15.
12. Bataller R., Brenner D. A. Liver fibrosis. J. Clin. Invest, 2005, Vol. 115, no. 2, pp. 209-218.
13. Bruno C.M., Valenti M., Bertino G., Ardiri A., Consolo M., Mazzarino C.M., Amoroso A., Neri S. Altered pattern of circulating matrix metalloproteinases -2, -9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. Panminerva Med, 2009. Vol. 51, no. 4, pp. 191-196.
14. Elkington P.T.G., O’Kane C.M., Friedland J.S. The paradox of matrix metalloproteinases in infectious disease. Clin. Experiment. Immunol, 2005, Vol. 142, no. 1, pp. 12-20.
15. Friedman S.L. Mechanisms of hepatic fibrogenesis. Gastroenterology, 2008, Vol. 134, no. 6, pp. 1655-1669.
16. Ghaleb H. A., Salah S. A novel hypothesis for pathophysiology of hepatitis fibrosis in hepatitis C viral infection. Hypothesis, 2011, Vol. 9, no. 1, pp. 1-5.
17. Greenbaum L.E., Wells R.G. The role of stem cells in liver repair and fibrosis. Int. J. Biochem. Cell Biol., 2011, Vol. 43, no. 2, pp. 222-229.
18. Jiao J., Friedman S.L., Aloman C. Hepatic fibrosis. Curr. Opin. Gastroenterol., 2009, Vol. 25, no. 3, pp. 223-229.
19. Mormone E., George J., Natalia Nieto N. Molecular pathogenesis of hepatic fibrosis and current therapeutic approaches. Chem. Biol. Interact., 2011, Vol. 193, no. 3, pp. 225-231.
20. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMP. Cardiovasc. Res., 2006, Vol. 69, no. 3, pp. 562-573.
21. Shiomi T., Lemaître V., D’Armiento J., Okada Y. Matrix metalloproteinases, a disintegrin and metalloproteinases, and a disintegrin and metalloproteinases with thrombospondin motifs in non-neoplastic diseases. Patholog. Int., 2010, Vol. 60, no. 7, pp. 477-496.
22. Tarrats N., Moles A., Morales A., García-Ruiz C., Fernández-Checa J.C., Marí M. Critical role of the TNFreceptor 1 but not 2 in hepatic stellate cell proliferation, extracellular matrix remodeling and liver fibrogenesis. Hepatology, 2011, Vol. 54, no. 1, pp. 319-327.
23. Valva P., Casciato P., Diaz Carrasco J.M., Gadano A., Galdame O., Galoppo M.C., Mullen E., De Matteo E., Preciado M.V. The role of serum biomarkers in predicting fibrosis progression in pediatric and adult hepatitis С virus chronic infection. PLoS One, 2011, Vol. 6, no. 8, pp. 1-10.
24. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J. Pathol., 2008, Vol. 214, no. 2, pp. 199-210.
Review
For citations:
Gorelova I.S., Sklyar L.F., Markelova E.V., Simakova A.I., Zenin I.V. EXTRACELLULAR MATRIX CONDITION IN CASE OF HCVASSOCIATED LIVER FIBROSIS. Medical Immunology (Russia). 2017;19(1):35-44. (In Russ.) https://doi.org/10.15789/1563-0625-2017-1-35-44
Views:
912
Email this article 